WAP
CBPO

Wealthcare Advisory Partners’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Wealthcare Advisory Partners’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5
Closed – – 1329
2017
Q4 		$0 Buy
+5
New +$416 ﹤0.01% 1240

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wealthcare Advisory Partners's CBPO Position: Q1 2018 in Review

Wealthcare Advisory Partners sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2018, closing a stake of 5 shares.

Wealthcare Advisory Partners first reported a position in CBPO in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2018.

  • Wealthcare Advisory Partners reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 5 China Biologic Products Holdings, Inc. shares in Q1 2018.
  • Wealthcare Advisory Partners first reported a position in China Biologic Products Holdings, Inc. in Q4 2017 and held it in 1 quarter.
  • Wealthcare Advisory Partners's China Biologic Products Holdings, Inc. position peaked at $0 in Q4 2017.
  • 86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.